

**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 55265

**Manuscript Type:** ORIGINAL ARTICLE

*Retrospective Study*

**Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China**

Wang DX *et al.* Lenvatinib for HCC in China

Dong-Xu Wang, Xu Yang, Jian-Zhen Lin, Yi Bai, Jun-Yu Long, Xiao-Bo Yang,  
Samuel Seery, Hai-Tao Zhao

**Abstract**

### Match Overview

|    |   |     |
|----|---|-----|
| 1  | <b>Crossref</b> 83 words<br>Takeshi Hatanaka, Satoru Kakizaki, Tamon Nagashima, Masashi Namikawa et al. "Analyses of objective respons                      | 2%  |
| 2  | <b>Internet</b> 42 words<br>crawled on 22-Nov-2018<br><a href="http://www.esmo.org">www.esmo.org</a>  | 1%  |
| 3  | <b>Internet</b> 41 words<br>crawled on 29-Jan-2020<br><a href="http://www.mdpi.com">www.mdpi.com</a>  | 1%  |
| 4  | <b>Internet</b> 32 words<br>crawled on 19-Apr-2020<br><a href="http://www.dovepress.com">www.dovepress.com</a>  | 1%  |
| 5  | <b>Crossref Posted Content</b> 24 words<br>Tetsu Tomonari, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka et al. "Therapeutic Efficacy and Safety of Lenvat | <1% |
| 6  | <b>Crossref</b> 21 words<br>Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, Aya ko Urabe et al. "Therapeutic efficacy of lenvatinib in hej ...              | <1% |
| 7  | <b>Internet</b> 21 words<br>crawled on 05-Mar-2020<br><a href="http://cslide.ctimeetingtech.com">cslide.ctimeetingtech.com</a>                              | <1% |
| 8  | <b>Internet</b> 14 words<br>crawled on 26-May-2020<br><a href="http://ar.iiarjournals.org">ar.iiarjournals.org</a>  | <1% |
| 9  | <b>Internet</b> 14 words<br>crawled on 03-Jun-2020<br><a href="http://ilca-online.org">ilca-online.org</a>  | <1% |
| 10 | <b>Internet</b> 13 words<br>crawled on 28-Mar-2019<br><a href="http://link.springer.com">link.springer.com</a>  | <1% |
| 11 | <b>Internet</b> 13 words<br>crawled on 28-Mar-2020<br><a href="http://onlinelibrary.wiley.com">onlinelibrary.wiley.com</a>                                  | <1% |



Efficacy and Safety of Lenvatinib for Patients with Advanc



ALL

IMAGES

VIDEOS

20,400 Results

Any time ▼

### Safety and efficacy profile of lenvatinib in cancer ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5190117>

Jul 12, 2016 · **Study** characteristics. Of the studies that were included in the final analysis, 3 studies were based on thyroid cancer **patients**, 5 evaluated **advanced** solid tumors, 1 evaluated non-small-cell lung cancer, 1 was based on melanoma, 2 were performed on metastatic renal cell **carcinoma**, 1 was on **advanced hepatocellular carcinoma** and 1 on healthy adults.

**Cited by:** 21**Author:** Chenjing Zhu, Xuele Ma, Yuanyuan Hu, ...**Publish Year:** 2016

### Complete response to the combination of Lenvatinib and ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839182>

Nov 08, 2019 · Background. **Hepatocellular carcinoma** (HCC) is the fifth leading cause of cancer death in the United States with a 5-year survival rate of 18% for all stages [] and its incidence rate is rising faster than that of any other cancer in both men and women []. Rates of both incidence (18.3 per 100,000) and mortality (17.1 per 100,000) are 2 to 3 times higher in **China** than those estimated in most ...

**Author:** Zhaonan Liu, Xingjie Li, Xuequn He, Y... **Publish Year:** 2019





ALL

IMAGES

VIDEOS

29,600 Results

Any time ▾

## [The Efficacy and Safety of Apatinib Treatment for Patients ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096375>

Jul 16, 2018 · **Patients** Characteristics. A total of 32 **patients** with refractory or relapsed liver cancer were included in this **retrospective study**. **Patient** characteristics at baseline were summarized in Table Table1. 1. 22 **patients** (69%) were male and 24 **patients** (75%) were older than 65. Most of the **patients** (78%) were diagnosed as **hepatocellular carcinoma**.

Cited by: 4

Author: Liu Zhen, Chen Jiali, Fang Yong, Xufeng ...

Publish Year: 2018

## [Efficacy and safety of lenvatinib \(LEN\) in Korean patients ...](#)

<https://www.researchgate.net/publication/339033970...>

Efficacy and safety of lenvatinib (LEN) in Korean **patients** (pts) with advanced **hepatocellular carcinoma** (aHCC): Multicenter retrospective analysis.

## [Clinical features of lenvatinib for unresectable ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346240>

Dec 21, 2018 · 1. INTRODUCTION. For treatment of unresectable **hepatocellular carcinoma** (u-HCC), tyrosine kinase inhibitors (TKIs), such as sorafenib (SOR) 1, 2 and regorafenib (REG), 3, 4 have been introduced. SOR was developed as a first-line agent for u-HCC, while REG is used as second-line therapy in **patients** who show good tolerability and progressive disease (PD) with SOR.

Cited by: 21

Author: Atsushi Hiraoka, Takashi Kumada, Kazuy...

Publish Year: 2019

## [\(PDF\) Efficacy and Safety of apatinib in patients with ...](#)

<https://www.researchgate.net/publication/322566395...>

The purpose of this study is to investigate the **efficacy** and **safety** of apatinib in **patients** with advanced colorectal cancer for whom at least two lines of prior chemotherapy had failed.

## [Clinical features of lenvatinib for unresectable ...](#)

<https://www.onlinelibrary.wiley.com/doi/full/10.1002/cam4.1909>

Dec 21, 2018 · 1 INTRODUCTION. For treatment of unresectable **hepatocellular carcinoma** (u-HCC), tyrosine kinase inhibitors (TKIs), such as sorafenib (SOR) 1, 2 and regorafenib (REG), 3, 4 have been introduced. SOR was developed as a first-line agent for u-HCC, while REG is used as second-line





ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

30,000 Results

Any time ▼

## [The Efficacy and Safety of Apatinib Treatment for Patients ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096375>

Jul 16, 2018 · **Patients** Characteristics. A total of 32 **patients** with refractory or relapsed liver cancer were included in this **retrospective study**. **Patient** characteristics at baseline were summarized in Table Table1. 1. 22 **patients** (69%) were male and 24 **patients** (75%) were older than 65. Most of the **patients** (78%) were diagnosed as **hepatocellular carcinoma**.

**Cited by:** 4**Author:** Liu Zhen, Chen Jiali, Fang Yong, Xufeng ...**Publish Year:** 2018

## [Clinical features of lenvatinib for unresectable ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346240>

Dec 21, 2018 · 1. INTRODUCTION. For treatment of unresectable **hepatocellular carcinoma** (u-HCC), tyrosine kinase inhibitors (TKIs), such as sorafenib (SOR) 1, 2 and regorafenib (REG), 3, 4 have been introduced. SOR was developed as a first-line agent for u-HCC, while REG is used as second-line therapy in **patients** who show good tolerability and progressive disease (PD) with SOR.

**Cited by:** 21**Author:** Atsushi Hiraoka, Takashi Kumada, Kazuy...**Publish Year:** 2019

## [Efficacy and safety of lenvatinib \(LEN\) in Korean patients ...](#)

<https://www.researchgate.net/publication/339033970...>

Request PDF | **Efficacy and safety of lenvatinib** (LEN) in Korean **patients** (pts) **with advanced hepatocellular carcinoma** (aHCC): Multicenter **retrospective** analysis. | 490 Background: LEN has ...

## [\(PDF\) Efficacy and Safety of apatinib in patients with ...](#)

<https://www.researchgate.net/publication/322566395...>

**Efficacy and Safety** of apatinib in **patients** with intermediate/**advanced hepatocellular carcinoma**: A prospective observation **study** Article (PDF Available) in Medicine 97(3):e9704 · January 2018 ...

## [Clinical features of lenvatinib for unresectable ...](#)